Patents Represented by Attorney, Agent or Law Firm Valeta A. Gregg, Esq.
  • IL-1 receptor based cytokine traps
    Patent number: 6927044
    Abstract: Fusion polypeptides capable of binding interleukin-1 (IL-1) to form a nonfunctional complex are provided and nucleic acid molecules encoding the fusion polypeptides. The fusion ploypeptides form dimers to function as IL-1 antagonists.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: August 9, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Neil Stahl, George D. Yancopoulos
  • Isolating cells expressing secreted proteins
    Patent number: 6919183
    Abstract: A method for identifying and isolating cells which produce secreted proteins. This method is based upon a specific characteristic or the expression level of the secreted protein by transiently capturing the secreted protein on the surface of an individual cell, allowing selection of rare cell clones from a heterogeneous population. Also provided is the use of this method to generate cells which produce a desired level of secreted protein or secreted protein of a particular characteristic(s), and organisms which possess such cells. In particular, the method allows rapid isolation of high expression recombinant antibody-producing cell lines, or may be applied directly to rapid isolation of specific hybridomas, or to the isolation of antibody-producing transgenic animals. This method is applicable for any cell which secretes protein.
    Type: Grant
    Filed: January 16, 2002
    Date of Patent: July 19, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Neil Stahl, Gang Chen, George D. Yancopoulos
  • Methods of stimulating cartilage formation
    Patent number: 6908744
    Abstract: The disruption of the murine ROR2 gene leads to profound skeletal abnormalities, with essentially all endochondrally derived bones foreshortened and/or misshapen, albeit to differing degrees. ROR2 is selectively expressed in the chondrocytes of all developing cartilage anlagen, where it plays a critical role during initial growth and patterning, as well as subsequently in the proliferating chondrocytes of mature growth plates, where it is required for normal expansion. As ROR2 appears to play a critical role in cartilage formation and it may be useful in developing therapeutic strategies to treat diseases of cartilage such as osteoarthritis.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: June 21, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Thomas M. DeChiara, Carrie A. Kimble, George D. Yancopoulos, Robert Kimble
  • TIE-2 ligand-4
    Patent number: 6881395
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: April 19, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Pamela F. Jones, George D. Yancopoulos
  • Tyrosine kinase receptors and ligands
    Patent number: 6852838
    Abstract: The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: February 8, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, David J. Glass, David C. Bowen, George D. Yancopoulos
  • DCR-5 bone affecting ligand
    Patent number: 6846908
    Abstract: DCR5, a protein related to DAN (Differential-screening-selected gene Aberrative in Neuroblastoma) and related nucleic acids are provided. Included are natural DCR5 homologs from several species and proteins comprising a DCR5 domain having specific activity, particularly the ability to antagonize a bone morphogenetic protein. The proteins may be produced recombinantly from transformed host cells with the subject nucleic acids. Also provided are isolated hybridization probes and primers capable of specifically hybridizing with the disclosed genes, specific binding agents and methods of making and using the subject compositions.
    Type: Grant
    Filed: September 15, 2003
    Date of Patent: January 25, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Aris N. Economides, Neil Stahl
  • Tie-2 ligand-3
    Patent number: 6846914
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: January 25, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Pamela F. Jones, George D. Yancopoulos
  • Methods of treating inflammatory skin diseases
    Patent number: 6833349
    Abstract: Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. Also disclosed are methods of treating diseases in which plasma leakage and/or vascular permeability occurs, for example, inflammatory skin diseases.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: December 21, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Yuping Xia, John S. Rudge, George D. Yancopoulos
  • Expressed ligand—vascular intercellular signalling molecule
    Patent number: 6825008
    Abstract: The present invention provides for a modified TIE-2 ligand which has been altered by addition, deletion or substitution of one or more amino acids, or by way of tagging, with for example, the Fc portion of human IgG-1, but which retains its ability to bind the TIE-2 receptor. The invention further provides for a modified TIE-2 ligand which is a chimeric TIE-2 ligand comprising at least a portion of a first TIE-2 ligand and a portion of a second TIE-2 ligand which is different from the first. In a specific embodiment, the invention further provides for a chimeric TIE ligand comprising at least a portion of TIE-2 Ligand-1 and a portion of TIE-2 Ligand-2. In addition the present invention provides for isolated nucleic acid molecule encoding the modified TIE-2 ligands described.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: November 30, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Samuel Davis, George D. Yancopoulos
  • Methods of using cytokine antagonists to treat HIV infection and AIDS
    Patent number: 6811780
    Abstract: The invention is methods of using cytokine antagonists to treat HIV. In particular, the invention is methods of treating HIV using L-4 and IL-13 cytokine antagonists, including cytokine traps and anti-IL-4 or anti-IL-13 antibodies. The invention also includes augmenting the efficacy of HIV vaccination by co-administration of the vaccine with IL-4 and IL-13 cytokine antagonists.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: November 2, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Eric S. Furfine, Neil Stahl
  • Use of ciliary neurotrophic factor
    Patent number: 6767894
    Abstract: Compositions and methods for the intranasal or respiratory administration of ciliary neurotrophic factor proteins, especially in the treatment of obesity and gestational or adult onset diabetes.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: July 27, 2004
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vivien W. Wong, Ellen M. Koehler-Stec, Neil Stahl
  • Stabilized aqueous peptide solutions
    Patent number: 6384016
    Abstract: Aqueous compositions comprising at least one peptide selected from glucagon, GLP-1, and analogues and derivatives thereof together with a stabilizing and solubilizing amount of at least one detergent, said detergent having at least 2 positive charges, at least 2 negative charges, or a combination of at least one positive charge and at least one negative charge.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: May 7, 2002
    Assignee: Novo Nordisk A/S
    Inventor: Niels C. Kaarsholm
  • cis3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
    Patent number: 6316494
    Abstract: The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: November 13, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Poul Jacobsen, Svend Treppendahl, Paul Stanley Bury, Anders Kanstrup, Lise Brown Christiansen
  • Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
    Patent number: 6316489
    Abstract: This invention relates to (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine D-tartrate, preparation thereof and use as therapeutic agent.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: November 13, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Claus Ulrich Jessen, Petra Christine Lugstein
  • Compounds, their preparation and use
    Patent number: 6300339
    Abstract: The present invention relates to compounds of formula (I) wherein A, B, Q, T, X, Y, Z, R5, R6, R7, R8, Ar, k, m, n and p are as defined in the specification. These compounds are useful in treating or preventing conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: October 9, 2001
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Treatment of Infertility
    Patent number: 6281013
    Abstract: In an in vitro fertilization method, a woman is treated with a hypothalamic hormone and/or a pituitary hormone or an agonist or antagonist thereof or an active derivative thereof for a short period of time and, thereafter, using in vitro oocyte maturation egg or eggs are retrieved from the woman and are maturated using a meiosis activating compound.
    Type: Grant
    Filed: March 20, 2000
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Christian Grøndahl
  • Method of treating gastrointestinal motility disorders
    Patent number: 6281233
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • Method of treating gastrointestinal motility disorders
    Patent number: 6281232
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 28, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
    Patent number: 6277991
    Abstract: The present invention relates to the use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the use of triaza-spiro compounds of formula wherein R1, R2, R3, R4, R5, z and n are defined in the specification, for the treatment of migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: August 21, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Rolf Hohlweg, Brett Watson, Christain Thomsen
  • Treatment of type 1 diabetes
    Patent number: 6274549
    Abstract: Insulin analogues which are substantially devoid of hypoglycemic effect can be used for treating of delaying the onset of type 1 diabetes or ameliorating of an early stage thereof in a mammal at risk of developing diabetes.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Dyrberg, Anne Worsaae